• OFID 2018:5 (Suppl 1) • Poster Abstracts opportunities and washes are recorded. eHH after CDI patient contact and any patient contact were collected. eHH adherence (using an ABHR or soap dispenser within 1 minute of room exit) was calculated overall and stratified by soap and water vs. ABHR. The primary outcome was eHH adherence using soap and water vs. ABHR after contact with a CDI patient. The secondary outcome was eHH adherence after CDI patient contact compared with all patients with and without CDI.
The Effect of Probiotics on the Incidence of Clostridium difficile
Background. Currently there is conflicting evidence regarding probiotics affecting the incidence and/or severity of Clostridium difficile infection (CDI). According to the IDSA guidelines, there are insufficient data to support the use of probiotics as primary prophylaxis of CDI. The primary objective of this study was to evaluate whether the administration of probiotics is efficacious for CDI prophylaxis in patients who are on antibiotics making them at increased risk for contracting CDI.
Methods. The study is an Institutional Review Board approved retrospective cohort study looking at patients who were admitted to NYU Winthrop University Hospital and received at least one dose of antibiotics considered high-risk of inducing CDI. Patients were grouped according to concurrent probiotic use and the association between probiotic use and incident CDI was examined. A model for incident CDI adjusting for number of concurrent antibiotics, patient age, proton pump inhibitors, histamine receptor antagonists, presence of colitis, and chemotherapy was also estimated. Microbiology reports were analyzed for up to 12 weeks post initial administration of antibiotics to determine whether patient acquired CDI. If no CDI occurred during the admission or post discharge, data was censored at 12 weeks.
Results. Of 2,208 patients, 1,502 (68%) were included in the interim analysis. Ninety-six out of 1,502 patients (6.39%) had CDI within 12 weeks of antibiotics initiation. One hundred thirty-five (9%) were on probiotics during antibiotic use and 1,367 (91%) were not. Of those taking probiotics, 11.1% had an incident of CDI and of those not taking probiotics, 5.9% had an incident of CDI with a relative risk of 1.88 (1.11, 3.16) and a P = 0.02. After adjustment, although a positive association between probiotics and CDI was still observed, it was not statistically significant (P = 0.24)
Conclusion. Based on the interim analysis, probiotics were associated with a higher risk of CDI in univariate analysis, however, when adjusted for several confounding factors this association, while still positive, was no longer statistically significant. Further data collection is ongoing to corroborate these results. Background. Antibiotic stewardship programs (ASPs) have been successful in reducing the incidence of Clostridium difficile (CDI) by reducing patient exposure to antibiotics, especially fluoroquinolones. Proton pump inhibitors (PPIs), while less pronounced as a risk factor for CDI, are widespread in their use, often for much longer durations than most courses of antibiotics. PPI stewardship may be a potential target for ASPs.
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Estimating the Effect of Proton Pump Inhibitor Stewardship in Reducing
Methods. We used a mathematical model of C. difficile transmission in an ICU to estimate the effects of a co-occurring antibiotic and PPI stewardship program. This approach captured any synergistic dynamics between the two interventions (e.g., patients taking both PPIs and antibiotics) while being able to independently estimate their effects. This model simulated for five years and 5,000 iterations, with the reduction in antibiotic and PPI use independently varied independently between 0% and 40%. The rates of C. difficile were then estimated using Poisson regression models accounting for admission volume.
Results. Both antibiotic and PPI stewardship reduced the number of incident C. difficile cases within the simulated ICU. A 30% decrease in fluoroquinolone use corresponded with a 21.9% decrease in incident C. difficile cases (P < 0.001), while a 30% decrease in PPI use corresponded with a 9.1% reduction (P < 0.001) in incident cases. There was no evidence of a synergistic effect between the two interventions (P = 0.60). PPI stewardship also decreased length of stay, resulting in a 7% increase in admissions in the simulated ICUs (P < 0.001).
Conclusion. PPI stewardship might prove a valuable adjunct to existing antibiotic stewardship programs. The reductions in C. difficile transmission were more modest for PPI stewardship as compared with programs targeting fluoroquinolones. PPI stewardship, however, may reach different patient populations, and may represent an additional area for substantial improvement even in facilities that have made substantial gains in reducing fluoroquinolone use.
Disclosures.All authors: No reported disclosures. Background. Hospital-onset Clostridium difficile infection (HO-CDI) affects over 100,000 patients in the United States each year. Due to a rising rate of HO-CDI at Denver Health, a multifaceted CDI prevention plan was implemented which included a probiotic intervention. The purpose of this study was to describe the implementation and uptake of the probiotic intervention.
Implementation of a Probiotic for the Primary Prevention of Hospital-Onset
Methods. This is a retrospective study of adult inpatients who received antibiotics considered high-risk for the development of CDI from March 2017 to March 2018. In March 2017, a Best Practice Advisory (BPA) was implemented to advise providers to order Bio-K+ (L. acidophilus, L. casei, and L. rhamnosus) when they signed an order for a high-risk antibiotic. The BPA allowed providers to order or decline the probiotic directly from the BPA. The BPA was suppressed in patients who were pregnant, immunocompromised, unable to take oral medications, or had active CDI. The primary outcome was the proportion of patients for whom Bio-K+ was prescribed in the first year. Secondary outcomes include CDI rates before and after the intervention and adverse events defined as a positive Lactobacillus culture.
Results. The BPA fired in 3,840 cases, and Bio-K+ was ordered in 94.8% of these. For patients who received a high-risk antibiotic for at least 24 hours, there were 2,636 courses of Bio-K+ prescribed for 2,324 unique patients for a median duration of 3 days. The HO-CDI rates for 1 year pre-and postintervention were 0.75 and 0.60 cases per 1,000 patient days, respectively (P = 0.16). Lactobacillus was cultured in 11 patients; five patients received Bio-K+ prior to culture. The positive cultures were from abdominal fluid (4) and sputum (1). There were no positive blood cultures in patients who received the probiotic.
Conclusion. A probiotic intervention for the prevention of CDI implemented via BPA had excellent provider uptake. As part of a multifaceted CDI action plan, a probiotic intervention was well received and had a low risk of serious adverse events. Results. One thousand sixty-four unique patients were included in this study. Overall, 778 patients received CTX-D and 286 received CTX-A. Among patients who received CTX-D, 2 patients developed CDI, compared with five patients who received CTX-A (relative risk, 0.15; 95% confidence interval, 0.03-0.75; P = 0.02). The mean time to onset of CDI from initiation of CTX-D was 22 days compared with 9.2 days from initiation of CTX-A.
Conclusion. In this cohort of non-ICU patients with CAP, CTX-D was associated with a reduced incidence of CDI. Further studies are necessary to confirm these preliminary findings to optimize clinical practice, while minimizing potential adverse outcomes associated with antimicrobial use.
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